logo
Plus   Neg
Share
Email

Gilead: Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta

Biopharmaceutical company Gilead Sciences Inc. (GILD) announced Sunday that its unit Kite revealed long-term follow-up data from the pivotal ZUMA-1 study of Yescarta (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma.

Yescarta is the first chimeric antigen receptor T or CAR T cell therapy to be approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma or DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Yescarta is not indicated for patients with primary central nervous system lymphoma.

Kite, focused on chimeric antigen receptor and T cell receptor engineered cell therapies, noted that with a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission.

Detailed results were presented at the Annual Meeting of the American Society of Hematology in Atlanta and published in The New England Journal of Medicine.

Sattva Neelapu, ZUMA-1 Co-Lead Investigator, said, "As observed in the SCHOLAR-1 study, treatment options for patients with refractory large B-cell lymphoma have yielded a median overall survival of just six months, with fewer than ten percent of patients achieving complete remission. The durability of response seen with Yescarta in this long-term follow-up reinforces the major advance that CAR T therapy represents for these patients."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT